Sun Pharma stands out as a structurally strong, long-term compounder in the Indian pharma space, with multiple levers aligning for sustained upside.

The company’s specialty portfolio continues to be the key growth engine, particularly in the US market where products like Ilumya are gaining steady traction. This shift toward high-margin specialty therapies is gradually reducing dependence on commoditized generics, supporting both revenue visibility and margin expansion. Domestically, Sun Pharma maintains leadership in chronic therapies, benefiting from strong doctor relationships and brand equity. India growth remains resilient, driven by rising healthcare awareness, pricing power in select segments, and expansion into Tier 2/3 markets. Operationally, the company has demonstrated consistent improvement in EBITDA margins, supported by better product mix, cost discipline, and resolution of key regulatory overhangs. The remediation of past USFDA issues has meaningfully reduced compliance risk, a factor that previously weighed on valuations. Financially, Sun Pharma is in a robust position with strong cash flows, low leverage, and the ability to fund both R&D and strategic acquisitions. Continued investment in complex generics and specialty pipelines provides optionality for future growth. From a valuation perspective, while the stock may not appear “cheap” on traditional metrics, the premium is justified by its superior return ratios, earnings visibility, and transition toward a differentiated pharma model. Overall, Sun Pharma offers a compelling mix of stability and growth. With improving global positioning, a strengthening specialty franchise, and consistent execution, the company remains well-placed to deliver steady compounding for long-term investors.